Cargando…
CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial
INTRODUCTION: Faster-acting insulin aspart (Fiasp) is approved for use in pregnancy and lactation, but no clinical study has evaluated its effects during this life stage in women with pre-existing diabetes. The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspar...
Autores principales: | Nørgaard, Sidse Kjærhus, Mathiesen, Elisabeth Reinhardt, Nørgaard, Kirsten, Clausen, Tine Dalsgaard, Damm, Peter, Ringholm, Lene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043014/ https://www.ncbi.nlm.nih.gov/pubmed/33837106 http://dx.doi.org/10.1136/bmjopen-2020-045650 |
Ejemplares similares
-
Dietary Advice to Support Glycaemic Control and Weight Management in Women with Type 1 Diabetes during Pregnancy and Breastfeeding
por: Ringholm, Lene, et al.
Publicado: (2022) -
Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin
por: Do, Nicoline Callesen, et al.
Publicado: (2023) -
Pregnancy outcomes in women with type 1 diabetes using insulin degludec
por: Ringholm, Lene, et al.
Publicado: (2022) -
Insulin Requirements in Type 1 Diabetic Pregnancy: Do twin pregnant women require twice as much insulin as singleton pregnant women?
por: Callesen, Nicoline F., et al.
Publicado: (2012) -
Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects
por: Shiramoto, Masanari, et al.
Publicado: (2021)